| This article has been cited by |
| 1 | Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent | |
| Lisa M.C. van Hoogstraten,J. Alfred Witjes,Richard P. Meijer,Theodora M. Ripping,Lambertus A. Kiemeney,Katja K.H. Aben |
| BJU International.2022;130(6)764 |
| [DOI] |
|
| 2 | Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations | |
| Hye Won Lee,Whi-An Kwon,La Ngoc Thu Nguyen,Do Thanh Truc Phan,Ho Kyung Seo |
| Cancers.2023;15(4)1323 |
| [DOI] |
|
| 3 | Should we care more about SPARE? | |
| Eugene K. Lee,Ashish M. Kamat |
| BJU International.2017;120(5)605 |
| [DOI] |
|
| 4 | FOXJ1 promotes bladder cancer cell growth and regulates Warburg effect | |
| Shaozhong Xian,Donghao Shang,Guangqi Kong,Ye Tian |
| Biochemical and Biophysical Research Communications.2018;495(1)988 |
| [DOI] |
|
| 5 | Trimodal therapy for muscle-invasive bladder cancer | |
| Joachim Mathes,Steffen Rausch,Tilman Todenhöfer,Arnulf Stenzl |
| Expert Review of Anticancer Therapy.2018;18(12)1219 |
| [DOI] |
|
